What are the side effects of Requip (ropinirole)?

Requip (Ropinirole) Side Effects

Ropinirole causes significant adverse effects including somnolence, dizziness, nausea/vomiting, and a substantial risk of augmentation with long-term use, which is why the 2025 AASM guidelines now recommend against its standard use for restless legs syndrome. 1

Common Side Effects

Most Frequent Adverse Events

The FDA-approved labeling and clinical evidence identify these primary side effects 2:

Gastrointestinal:

• Nausea (37.2% vs 9.4% placebo) - This is the most common side effect, representing nearly 50% of all adverse events 3
• Vomiting (10.9% vs 2.6% placebo) - Risk is 4.6 times higher than placebo 3
• Constipation
• Upset stomach/abdominal pain

Neurological:

• Somnolence/drowsiness - Occurs frequently and can be severe
• Dizziness/vertigo - Clinically significant risk documented 1
• Headache
• Confusion

Cardiovascular:

• Orthostatic hypotension - Can cause fainting, particularly when starting therapy or increasing doses 2, 4
• Blood pressure fluctuations (both increases and decreases)
• Heart rate changes

Other:

• Fatigue/weakness/tiredness
• Leg swelling/edema
• Increased sweating

Serious and Long-Term Adverse Effects

Critical Safety Concerns (FDA Black Box Equivalent Warnings)

1. Sudden Sleep Attacks 2

• Patients may fall asleep during normal activities including driving
• Can occur without warning or drowsiness
• Risk increases with concomitant sedating medications

2. Augmentation 1

• This is the most significant long-term concern
• Symptoms appear earlier in the day (evening → afternoon → morning)
• Increased symptom intensity
• Spread to other body parts
• Rebound effects during night
• Clinically significant in observational studies with moderate undesirable effect size

3. Impulse Control Disorders 1, 2

• Pathological gambling
• Increased sexual urges and behaviors
• Compulsive shopping/spending
• Binge eating
• These are unusual behaviors that patients may not recognize as medication-related

4. Hallucinations and Psychotic-Like Behavior 2

• Seeing or hearing things that aren't real
• Confusion, excessive suspicion
• Aggressive behavior, agitation
• Delusional beliefs
• Disorganized thinking
• Higher risk in Parkinson's patients and at higher doses

5. Withdrawal Symptoms 2

• Apathy, anxiety, depression
• Fatigue, insomnia
• Sweating, pain
• Never stop abruptly - requires gradual taper

6. Withdrawal-Emergent Hyperpyrexia and Confusion 2

• Fever, muscular rigidity, altered consciousness
• Can occur with dose reduction or discontinuation

Clinical Context and Guideline Perspective

The 2025 AASM guidelines represent a significant shift in clinical practice 1:

Key Recommendation: The AASM now suggests against the standard use of ropinirole (conditional recommendation, moderate certainty of evidence) 1

Rationale:

• While 13 RCTs showed clinically significant improvements in disease severity and quality of life with small effect size
• The adverse event profile, particularly augmentation risk, outweighs benefits for routine use
• Augmentation showed clinically significant results in observational studies with moderate undesirable effect size

When It May Still Be Considered: Only in patients who place higher value on short-term symptom reduction and lower value on long-term adverse effects, particularly augmentation 1

Important Clinical Pitfalls

Prescribing Cascade Risk: A documented case showed ropinirole-induced orthostatic hypotension led to falls, hospital admissions, and unnecessary prescriptions for midodrine and compression stockings over 8 months before the root cause was identified 4. This is particularly problematic in elderly patients.

Dose-Related Considerations:

• Adverse events did not meet clinical significance for study withdrawal in pooled estimates 1
• However, individual patient tolerance varies significantly
• Start low, titrate slowly to minimize side effects

Drug Interactions:

• Smoking decreases effectiveness 2
• Alcohol increases drowsiness risk 2
• Other sedating medications compound sleep attack risk 2
• CYP1A2 metabolism means potential interactions with inhibitors/inducers 5

Monitoring Recommendations

Before Starting:

• Screen for daytime sleepiness or sleep disorders
• Assess blood pressure (sitting and standing)
• Document baseline symptom timing and severity
• Evaluate for impulse control issues

During Treatment:

• Monitor for augmentation: earlier symptom onset, increased intensity, spread to other body parts
• Assess orthostatic vital signs, especially after dose changes
• Screen for impulse control disorders at each visit
• Evaluate for sudden sleep episodes
• Watch for psychotic symptoms in at-risk patients

If Discontinuing:

• Taper gradually - never stop abruptly
• Monitor for withdrawal symptoms
• Watch for hyperpyrexia and confusion

The evidence strongly supports that ropinirole's adverse effect profile, particularly the risk of augmentation and impulse control disorders, necessitates careful patient selection and close monitoring, with current guidelines favoring alternative treatments for most patients 1, 2.